TW200512003A - Enhanced method of treatment of growth disorders - Google Patents
Enhanced method of treatment of growth disordersInfo
- Publication number
- TW200512003A TW200512003A TW093128039A TW93128039A TW200512003A TW 200512003 A TW200512003 A TW 200512003A TW 093128039 A TW093128039 A TW 093128039A TW 93128039 A TW93128039 A TW 93128039A TW 200512003 A TW200512003 A TW 200512003A
- Authority
- TW
- Taiwan
- Prior art keywords
- treatment
- enhanced method
- growth hormone
- growth disorders
- growth
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 208000037824 growth disorder Diseases 0.000 title abstract 2
- 102000018997 Growth Hormone Human genes 0.000 abstract 3
- 108010051696 Growth Hormone Proteins 0.000 abstract 3
- 239000000122 growth hormone Substances 0.000 abstract 3
- 230000002411 adverse Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 235000021588 free fatty acids Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychiatry (AREA)
- Zoology (AREA)
- Reproductive Health (AREA)
- Emergency Medicine (AREA)
- Virology (AREA)
- Gynecology & Obstetrics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ52838803 | 2003-09-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW200512003A true TW200512003A (en) | 2005-04-01 |
Family
ID=34374472
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW093128039A TW200512003A (en) | 2003-09-19 | 2004-09-16 | Enhanced method of treatment of growth disorders |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20070037861A1 (zh) |
| EP (1) | EP1667671A1 (zh) |
| JP (1) | JP2007505892A (zh) |
| AR (1) | AR045766A1 (zh) |
| BR (1) | BRPI0414175A (zh) |
| CA (1) | CA2538846A1 (zh) |
| TW (1) | TW200512003A (zh) |
| WO (1) | WO2005027894A1 (zh) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2059260E (pt) * | 2006-08-31 | 2013-09-03 | Novartis Ag | Composições farmacêuticas compreendendo hgh para distribuição oral |
| WO2012104838A1 (en) * | 2011-02-01 | 2012-08-09 | Mor Researchr Applications Ltd. | Use of hgh for the treatment of small for gestational age infants under two years of age |
| DK2988617T3 (da) | 2013-03-27 | 2023-11-27 | Nutritional Growth Solutions Ltd | Ernæringstilskud til vækstfremmelse |
| EP3939590B1 (en) * | 2015-09-21 | 2023-11-29 | Lumos Pharma, Inc. | Detecting and treating growth hormone deficiency |
| EP3426062A1 (en) | 2016-03-10 | 2019-01-16 | Enzymotec Ltd. | Lipid compositions and uses thereof |
| BR112021015799A2 (pt) | 2019-02-12 | 2022-01-18 | Mirum Pharmaceuticals Inc | Métodos para aumentar o crescimento em pacientes pediátricos com doença colestática do fígado |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1149583A3 (en) * | 2000-04-13 | 2001-11-14 | Pfizer Products Inc. | Combinations of corticotropin releasing factor antagonists and growth hormone secretagogues |
| IL145106A0 (en) * | 2000-08-30 | 2002-06-30 | Pfizer Prod Inc | Intermittent administration of a geowth hormone secretagogue |
-
2004
- 2004-09-14 JP JP2006526732A patent/JP2007505892A/ja active Pending
- 2004-09-14 EP EP04769431A patent/EP1667671A1/en not_active Withdrawn
- 2004-09-14 BR BRPI0414175-0A patent/BRPI0414175A/pt not_active IP Right Cessation
- 2004-09-14 US US10/572,699 patent/US20070037861A1/en not_active Abandoned
- 2004-09-14 CA CA002538846A patent/CA2538846A1/en not_active Abandoned
- 2004-09-14 WO PCT/IB2004/003063 patent/WO2005027894A1/en not_active Application Discontinuation
- 2004-09-16 TW TW093128039A patent/TW200512003A/zh unknown
- 2004-09-17 AR ARP040103364A patent/AR045766A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0414175A (pt) | 2006-10-31 |
| EP1667671A1 (en) | 2006-06-14 |
| US20070037861A1 (en) | 2007-02-15 |
| AR045766A1 (es) | 2005-11-09 |
| JP2007505892A (ja) | 2007-03-15 |
| CA2538846A1 (en) | 2005-03-31 |
| WO2005027894A1 (en) | 2005-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2005000055A (es) | Bioconversion estereoselectiva de dinitrilos alifaticos en acidos cianocarboxilicos. | |
| TW200603807A (en) | Method for the treatment of premenstrual and other female sexual disorders | |
| WO2007130474A3 (en) | Method of differentiating stem cells into cells of the endoderm and pancreatic lineage | |
| ATE365047T1 (de) | N-terminal monopegylierte menschliche wachstumshormon-konjugate, verfahren zu ihrer herstellung und ihre anwendung | |
| MY176679A (en) | Use of nutritional compositions for preventing disorders | |
| EP1485381B8 (en) | Azolylaminoazine as inhibitors of protein kinases | |
| HK1085140A1 (en) | Pharmaceutical compositions and method of using levodopa and carbidopa | |
| HK1096673A1 (en) | Compositions useful as inhibitors of protein kinases | |
| AU2003218215A1 (en) | Azolylaminoazines as inhibitors of protein kinases | |
| AU2003220300A1 (en) | Compositions useful as inhibitors of protein kinases | |
| IL182417A0 (en) | Mitotic kinesin inhibitors and methods of use thereof | |
| TW200602031A (en) | Antiinflammatory and pain-relieving agent for external, use | |
| ZA200810113B (en) | Method for the treatment and prevention of ocular disorders | |
| MXPA05007181A (es) | Cristales de la hormona de crecimiento humano y metodos para prepararlos. | |
| HK1075403A1 (en) | Treatment of mastalgia with 4-hydroxy tamoxifen | |
| MX366496B (es) | Metodos para preparar composiciones farmaceuticas que comprenden acetato de eslicarbazepina y metodos de uso. | |
| WO2006002096A3 (en) | Low doses of l-citrulline for treating diseases | |
| TW200512003A (en) | Enhanced method of treatment of growth disorders | |
| MXPA05008561A (es) | Uso de esteroides para tratar personas que sufren de trastornos oculares. | |
| ATE372114T1 (de) | Verfahren zur erhöhung des testosteronspiegels | |
| BR0306855A (pt) | Método para o tratamento de distúrbios cognitivos | |
| AU2003239813A1 (en) | Use of pleuromutilins for the treatment of disorders caused by helicobacter pylori | |
| WO2004043365A3 (en) | Method for treatment of premature ejaculation in humans | |
| WO2003070167A3 (en) | Therapeutic and prophylactic treatment of aging and disorders of aging in humans | |
| EP1597234A4 (en) | NEW COMPOUNDS |